Secondary Causes of ITP
Secondary ITP can result from autoimmune disorders, infections, lymphoproliferative diseases, medications, and other immune-mediated conditions that must be systematically excluded when evaluating thrombocytopenia. 1
Major Categories of Secondary ITP
The American Society of Hematology guidelines provide a comprehensive list of secondary causes that should be considered in all patients presenting with immune thrombocytopenia 1, 2:
Autoimmune Disorders
- Systemic lupus erythematosus (SLE) - one of the most common autoimmune associations
- Antiphospholipid syndrome - can present with thrombocytopenia as an isolated finding
- Evans syndrome - autoimmune thrombocytopenia occurring with concurrent autoimmune hemolytic anemia
- Autoimmune thyroid disease (particularly hypothyroidism, which was found to be the most common secondary cause in one large cohort at 21.5%) 3
- Common variable immune deficiency
Infectious Causes
The guidelines specifically highlight several infections requiring targeted evaluation and treatment:
Helicobacter pylori - ASH recommends screening for H. pylori in patients with ITP where eradication therapy would be used if positive (grade 2C), and that eradication therapy be administered when infection is confirmed (grade 1B) 1, 2. This was the second most common secondary cause (11.4%) in recent studies 3
HIV infection - Between 6-15% of HIV-infected patients develop thrombocytopenia 4. ASH strongly recommends testing all ITP patients for HIV (grade 1A) and treating the HIV infection with antiviral therapy before other ITP treatments unless clinically significant bleeding is present (grade 1A) 2
Hepatitis C virus (HCV) - ASH recommends testing all ITP patients for HCV (grade 1B) 2. HCV-related thrombocytopenia can occur even without overt liver disease and antiviral therapy should be considered when contraindications are absent (grade 2C) 1
Cytomegalovirus (CMV)
Varicella zoster virus
Epstein-Barr virus - particularly in children with acute-onset thrombocytopenia
Brucellosis - relevant in endemic regions 5
Lymphoproliferative Disorders
- Chronic lymphocytic leukemia (CLL) - a well-recognized cause where the malignant clone itself may drive immune-mediated platelet destruction 6
- Large granular T-lymphocyte leukemia
- Other lymphoproliferative diseases 1
Drug-Induced ITP
Medication side effects represent an important and potentially reversible cause of secondary ITP 1
Other Causes
- Bone marrow transplantation - as a complication
- Vaccination - particularly MMR vaccine in children, though this typically presents as acute thrombocytopenia 1
- COVID-19 infection - emerging data shows ITP can develop even after mild COVID-19 infection, sometimes with delayed onset during the recovery phase 7
Clinical Implications
The distinction between primary and secondary ITP matters clinically. Patients with secondary ITP tend to be older and report more fatigue, while those with primary ITP have higher rates of severe (grade 3/4) bleeding 3. The natural history, response to therapy, and management approach differ substantially between primary ITP and various secondary causes 8.
Diagnostic Approach
The 2019 ASH guidelines recommend 2:
- Testing for HCV and HIV in all adult ITP patients (grade 1B)
- Screening for H. pylori should be considered when eradication therapy would be pursued if positive (grade 2C)
- Further investigations if abnormalities beyond isolated thrombocytopenia are present in blood counts or smear (grade 2C)
- Bone marrow examination is not routinely necessary for typical ITP presentations, regardless of age (grade 2C) - this was confirmed by recent data showing baseline bone marrow examination did not detect secondary causes 3
Important Caveat
When autoimmune markers (ANA, anti-dsDNA, anticardiolipin antibodies, lupus anticoagulant) or infectious serologies are tested, positive results occur in 21-33% of ITP patients depending on the specific test 5, emphasizing the importance of systematic screening in appropriate clinical contexts rather than assuming all ITP is primary.